Several studies have shown that inhibition of the ATR pathway is selectively toxic to cancer cells with high oncogene-driven replication damage [47–50] and inhibition of the functional kinase activity of ATR sensitizes cancer cells to conventional DNA damaging chemotherapies, ionizing radiation and immunotherapy [51–55]. The gene discussed is ATR; the disease is cancer.